Milestone Pharmaceuticals Inc. Stock News

Renaissance Technologies LLC trimmed its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 50.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 107,554 shares of the companys stock after selling 108,846 shares during the period. Renaissance Technologies LLC owned about 0.36% of Milestone []

Zacks Investment Research upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a sell rating to a hold rating in a research note published on Thursday morning, Zacks.com reports. According to Zacks, Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular []

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Equities researchers at Oppenheimer boosted their FY2021 earnings estimates for Milestone Pharmaceuticals in a research report issued to clients and investors on Monday, November 15th. Oppenheimer analyst L. Gershell now forecasts that the company will post earnings of ($1.00) per share for the year, up from their previous estimate of []

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Research analysts at Piper Sandler raised their FY2021 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research report issued on Tuesday, November 16th. Piper Sandler analyst E. Tenthoff now anticipates that the company will earn ($0.97) per share for the year, up from their prior forecast of ($1.00). []

MONTREAL and CHARLOTTE, N.C., Nov. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative

MONTREAL and CHARLOTTE, N.C., Sept. 22, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovati

MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative

MONTREAL and CHARLOTTE, N.C., May 26, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to

- Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial - - Data Presented at the

MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative

MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative

If Milestone Pharmaceuticals' Etripamil nasal spray succeeds in clinical trials, MIST stock is going to see big growth. The post Milestone Pharmaceuticals Stock Is a Bet On Etripamil appeared first on

MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovativ

MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovati